相关实验视频

Updated: Jul 15, 2026

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Published on: May 30, 2015

在体内验证新的非侵入性PHP.eB AAVs作为对α-synucleinopathies的潜在治疗方法

Maria Fouka^1,2, Iraklis Tsakogias¹, Elena-Georgia Gialinaki¹

¹Biomedical Research Foundation Academy of Athens- BRFAA, Clinical- Experimental Surgery & Translational Research, Athens, Greece.

Acta neuropathologica communications

|September 30, 2025

概括

这项研究表明,使用新型病毒载体降低α-synuclein (aSyn) 蛋白水平可以减少帕金森病小鼠模型中的病理传播和运动缺陷. 这种方法为同核蛋白病变提供了一个有前途的治疗策略.

科学领域:

神经科学是一个神经科学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

帕金森病 (PD) 与α-synuclein (aSyn) 总积累有关.
了解aSyn在病理传播中的作用对于开发治疗方法至关重要.

研究的目的:

在PD小鼠模型中评估降低内源aSyn水平的治疗潜力.
评估一种用于透大脑的病毒载体的新型传递系统.

主要方法:

对表达Snca向性shRNA/miRNA的PHP.eB AAV载体进行系统注射.
在小鼠体内注射人类aSyn预先形成纤维素 (PFFs).
评估病毒转导,aSyn减少,病理和运动行为.

主要成果:

在多巴胺基神经元中,PHP.eB AAVs实现了广泛的大脑转导,并减少了内源性aSyn.
降低的aSyn水平减轻了pSer129-aSyn入,黑状腺退化和运动缺陷.
病理传播到其他大脑区域的病理减弱了.

结论:

细胞内aSyn蛋白负载在PD模型中对病理进展做出了重大贡献.
通过PHP进行aSyn降低疗法的非侵入性输送.eB AAVs显示了对synucleinopathies的治疗前景.

关键词:

在 AAV-PHP.eB 中.阿尔法-协同核蛋白是一种多巴氨基系统多巴氨基系统预制成形的纤维.微RNAs 是一个微型RNA.微RNAs 是一种小RNA.

更多相关视频

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector

Published on: February 28, 2016

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo

Published on: June 2, 2019

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...